Inflammatix Receives Breakthrough Device Designation from FDA for TriVerity™
Regulatory Milestone Designed to Expedite Path to FDA Clearance and CMS Coverage click to read more
Host Response Diagnostics
Delivering precision medicine on demand
Our immune system has developed targeted responses to different types of infections and other diseases over millions of years. We are developing an assay to rapidly measure this immune response using proprietary machine-learning algorithms to generate clinically actionable results. Faster diagnostics may support faster and smarter care decisions, and better patient outcomes.
Validated in numerous independent cohorts involving thousands of patients and published in leading medical journals, Inflammatix is developing an innovative point-of-care platform and test to aid in the diagnosis of acute infection and sepsis by measuring the patient’s immune response to bacteria and viruses.
Product in development, is not for sale, and does not have marketing approval or clearance from regulatory authorities in any jurisdiction.
Our tests are addressing significant clinical needs in acute infection and sepsis diagnosis that affect millions of people
Products in development, not for sale, and do not have marketing approval or clearance from regulatory authorities in any jurisdiction.
Based on US CDC numbers. Numbers also referenced from Martin, NEJM 2003; Donnelly, Antimicrob. Ag Chemo 2013; Hasegawa, PIDJ 2015; Goto, J Am Ger Soc 2016; Magill, NEJM 2014; Horeczko, West JEM 2014; Fleming-Dutra, JAMA 2016.
In the News
Recent notable news stories
Rapid Tests Continue Push Into Sepsis Market in 2023 as Competition Heats Up